Upadacitinib Nitroso impurity 1
Synchemia is a leading Manufacturer in pharmaceutical Nitrosamine compounds.Upadacitinib is used to treat moderate to severely active rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis (a type of arthritis in the spine) with objective signs of swelling, moderate to severe ulcerative colitis, moderate to severe Crohn's disease.Upadacitinib Nitroso impurity 1 is a highly toxic organic compound and a suspected human carcinogen. Handle the material carefully with proper safety measures.
Upadacitinib Nitroso impurity 1 CAS NO:NA Chemically represented as (3S,4R)-3-Ethyl-4-(3-nitroso-3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide . Synchemia is the leading manufacturing and exporter of Upadacitinib Nitroso impurity 1. We supply Upadacitinib Nitroso impurity 1 with detailed characterization data compliance with regulatory guidelines.
Make an Enquiry for Abacavir EP Impurity A
Related Products
| CAT No | SRC-N0142515 |
| CAS No | NA |
| Mol.F. | C15H20N2O5 |
| Mol.Wt. | 308.3 g/mol |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0142516 |
| CAS No | NA |
| Mol.F. | C18H23N3O6 |
| Mol.Wt. | 377.4 g/mol |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0142517 |
| CAS No | NA |
| Mol.F. | C26H31N3O6 |
| Mol.Wt. | 481.5 g/mol |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0142518 |
| CAS No | NA |
| Mol.F. | C22H31N3O6 |
| Mol.Wt. | 433.5 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142519 |
| CAS No | NA |
| Mol.F. | C15H26N2O5 |
| Mol.Wt. | 314.4 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142520 |
| CAS No | NA |
| Mol.F. | C3H3N3O |
| Mol.Wt. | 97.08 g/mol |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0142521 |
| CAS No | NA |
| Mol.F. | C24H25F2N9O |
| Mol.Wt. | 493.5 g/mol |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0142522 |
| CAS No | NA |
| Mol.F. | C24H24F2N10O2 |
| Mol.Wt. | 522.5 g/mol |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0142523 |
| CAS No | NA |
| Mol.F. | C8H7BFN3O3 |
| Mol.Wt. | 223.0 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142524 |
| CAS No | NA |
| Mol.F. | C10H14N4O |
| Mol.Wt. | 206.2 g/mol |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0142525 |
| CAS No | NA |
| Mol.F. | C27H31F2N9O2 |
| Mol.Wt. | 551.60 g/mol |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0142526 |
| CAS No | NA |
| Mol.F. | C27H31F2N9O2 |
| Mol.Wt. | 551.60 g/mol |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0142527 |
| CAS No | NA |
| Mol.F. | C27H32FN9O |
| Mol.Wt. | 517.61 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142528 |
| CAS No | NA |
| Mol.F. | C27H31F2N9O2 |
| Mol.Wt. | 551.60 g/mol |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0142529 |
| CAS No | NA |
| Mol.F. | C27H31F2N9O3 |
| Mol.Wt. | 567.60 g/mol |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0142530 |
| CAS No | NA |
| Mol.F. | C28H32N4O4 |
| Mol.Wt. | 488.6 g/mol |
| INV STATUS | In Stock |